Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BRNS
BRNS logo

BRNS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Barinthus Biotherapeutics PLC (BRNS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
0.630
1 Day change
-0.32%
52 Week Range
2.920
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

BRNS is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The technical setup is bearish, there is no supportive options or catalyst evidence, and both AI Stock Picker and SwingMax show no active buy signal. Given the weak trend and lack of clear fundamental momentum, the better call is to avoid buying now.

Technical Analysis

BRNS is in a bearish trend. MACD histogram is negative and worsening, indicating downside momentum. RSI_6 at 30.5 is near oversold but not yet a strong reversal signal. Moving averages are aligned bearishly with SMA_200 > SMA_20 > SMA_5, confirming a downtrend. Price at 0.6014 is below the pivot at 0.675 and close to S1 at 0.608, suggesting the stock is trading near short-term support but without confirmation of a bounce. The pattern-based forecast also points to weakness, with a 60% chance of further downside over the next day and week.

Positive Catalysts

  • No recent news was reported in the last week. There is no notable insider buying, hedge fund accumulation, or congress trading activity. The only mild positive is that the stock is near short-term support, which could allow a bounce, but there is no confirmed catalyst behind it.

Neutral/Negative Catalysts

  • Recent price action is weak, with the stock down on the regular session and still below key trend levels. MACD is negative and expanding, moving averages are bearish, and the short-term pattern outlook favors additional downside. Hedge funds and insiders are both neutral, and there is no recent news or congress trading support. No AI Stock Picker or SwingMax signal is active.

Financial Performance

No usable latest-quarter financial snapshot was provided, so there is not enough data to assess recent quarterly growth trends or the latest season's performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so Wall Street sentiment cannot be confirmed from the dataset. Based on the available information, the pros appear limited and the cons dominate: weak technical trend, no recent positive catalyst, and no active proprietary buy signal.

Wall Street analysts forecast BRNS stock price to rise
1 Analyst Rating
Wall Street analysts forecast BRNS stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.630
sliders
Low
4
Averages
4
High
4
Current: 0.630
sliders
Low
4
Averages
4
High
4
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$3 -> $4
AI Analysis
2025-11-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$3 -> $4
AI Analysis
2025-11-17
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Barinthus Biotherapeutics to $4 from $3 and keeps a Buy rating on the shares following the Q3 report.

People Also Watch